Rankings
▼
Calendar
ALNY FY 2016 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$42B
FY 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$47M
+14.8% YoY
Gross Profit
$47M
100.0% margin
Operating Income
-$425M
-900.3% margin
Net Income
-$410M
-869.6% margin
EPS (Diluted)
$-4.79
Cash Flow
Operating Cash Flow
-$308M
Free Cash Flow
-$372M
Stock-Based Comp.
$76M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$343M
Stockholders' Equity
$920M
Cash & Equivalents
$194M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$47M
$41M
+14.8%
Gross Profit
$47M
$41M
+14.8%
Operating Income
-$425M
-$296M
-43.4%
Net Income
-$410M
-$290M
-41.4%
← FY 2015
All Quarters
Q1 2016 →